Literature DB >> 8895543

Cisplatin-induced apoptosis and p53 gene status in a cisplatin-resistant human ovarian carcinoma cell line.

A Fajac1, J Da Silva, J C Ahomadegbe, J G Rateau, J F Bernaudin, G Riou, J Bénard.   

Abstract

Cisplatin-induced apoptosis and p53 gene status were analyzed in human ovarian carcinoma using a parental IGR-OV1 line and a derived cisplatin-resistant IGR-OV1/DDP subline. Compared with parental cells, cisplatin-resistant cells exhibited a 5-fold higher resistance index and a 2-fold longer doubling time. Cisplatin induced apoptosis in both cell lines, as assessed by cell morphology and the presence of a DNA ladder. However, high concentrations were necessary to induce apoptosis in resistant cells. These cells elicited a 5-fold decrease in the number of platinum atoms bound per nucleotide. IGR-OV1/DDP cells also exhibited enhanced drug efflux and a higher glutathione content. Our data suggest that the levels of cisplatin-DNA lesions are critical for drug sensitivity and apoptosis induction in this in vitro ovarian carcinoma model. Comparative analysis of the p53 gene in sensitive and resistant cells revealed the presence of the same heterozygous mutation in exon 5. A 2-fold increase in p53 mRNA and protein amounts was observed in resistant cells as assessed by Northern and Western blots, respectively. Immunocytochemical staining revealed a higher percentage of p53 stained nuclei in resistant cells. RT-PCR analysis of p53 transcripts showed that both wild-type and mutated alleles were transcribed in sensitive as well as in resistant cells. However, mutated transcripts were 1.5-fold more abundant than wild-type transcripts in sensitive cells, whereas they were 2-fold higher in resistant cells. In addition, mdm-2 protein was over-expressed in resistant cells. Our results address the question of the functionality of p53 protein and its possible role in apoptosis induction in this model. In resistant cells, p53 protein might be inactivated by 2 mechanisms: mutation and complexation with mdm-2 protein. Therefore, the presence of non-functional p53 in resistant cells might be involved in the relative failure of cisplatin-induced apoptosis in these cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8895543     DOI: 10.1002/(SICI)1097-0215(19960927)68:1<67::AID-IJC13>3.0.CO;2-3

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  Alterations in nuclear pore architecture allow cancer cell entry into or exit from drug-resistant dormancy.

Authors:  Yayoi Kinoshita; Tamara Kalir; Jamal Rahaman; Peter Dottino; D Stave Kohtz
Journal:  Am J Pathol       Date:  2011-11-07       Impact factor: 4.307

2.  BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.

Authors:  Britta Stordal; Kirsten Timms; Angela Farrelly; Danielle Gallagher; Steven Busschots; Mickaël Renaud; Julien Thery; Deborah Williams; Jennifer Potter; Thanh Tran; Greg Korpanty; Mattia Cremona; Mark Carey; Jie Li; Yang Li; Ozlem Aslan; John J O'Leary; Gordon B Mills; Bryan T Hennessy
Journal:  Mol Oncol       Date:  2013-01-31       Impact factor: 6.603

3.  Decreased transcription-coupled nucleotide excision repair capacity is associated with increased p53- and MLH1-independent apoptosis in response to cisplatin.

Authors:  Lawton J Stubbert; Jennifer M Smith; Bruce C McKay
Journal:  BMC Cancer       Date:  2010-05-14       Impact factor: 4.430

4.  Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells.

Authors:  P Yue; X Zhang; D Paladino; B Sengupta; S Ahmad; R W Holloway; S B Ingersoll; J Turkson
Journal:  Oncogene       Date:  2011-09-12       Impact factor: 9.867

5.  Preclinical Assessment of Low Doses of Cisplatin in the Management of Acute Promyelocytic Leukemia.

Authors:  Shaloam R Dasari; Venkatramreddy Velma; Clement G Yedjou; Paul B Tchounwou
Journal:  Int J Cancer Res Mol Mech       Date:  2015-10-15

6.  Key Players of Cisplatin Resistance: Towards a Systems Pharmacology Approach.

Authors:  Navin Sarin; Florian Engel; Florian Rothweiler; Jindrich Cinatl; Martin Michaelis; Roland Frötschl; Holger Fröhlich; Ganna V Kalayda
Journal:  Int J Mol Sci       Date:  2018-03-07       Impact factor: 5.923

7.  Cisplatin-resistant HeLa cells are resistant to apoptosis via p53-dependent and -independent pathways.

Authors:  Y Minagawa; J Kigawa; H Itamochi; Y Kanamori; M Shimada; M Takahashi; N Terakawa
Journal:  Jpn J Cancer Res       Date:  1999-12

8.  Temperature-sensitive ovarian carcinoma cell line (OvBH-1).

Authors:  Julia K Bar; Antonina Harlozinska; Sabine Kartarius; Mathias Montenarh; Ewa Wyrodek; Jan M Rodriguez Parkitna; Marian Kochman; Andrzej Ozyhar
Journal:  Jpn J Cancer Res       Date:  2002-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.